Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors

Table 4

Tumor response in patients receiving ≤3 lines and >3 lines treatment.

Best response	≤3 lines	>3 lines
CR,	0	0
PR,	5	1
SD,	5	6
PD,	4	4
ORR, (%)	35.7%	9.1%
DCR, (%)	71.4%	63.6%